Rockwell Medical Announces Extension of Multi-Year Distribution Agreement with Nipro Medical Corporation for Dialysis Concent...
June 11 2021 - 12:20PM
Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company
dedicated to transforming the treatment of iron deficiency and
anemia management and improving outcomes for patients around the
world, today announced that it extended its distribution agreement
with its long-term distribution partner, Nipro Medical Corporation
(NMC), for a period of three years through May 2024. The agreement
was originally initiated in 2008. With the extension of the
agreement, NMC will continue to distribute dialysis concentrates
manufactured by Rockwell Medical to numerous countries in Latin
America and the Caribbean. NMC is a leading renal, medical,
surgical and interventional radiology products manufacturer and a
major distributor of renal products in these regions.
“We have a longstanding relationship with Nipro
Medical Corporation, a partner of choice, and are pleased to extend
our distribution agreement to continue to bring important dialysate
concentrate products to patients,” said Russell Ellison, M.D.,
President and Chief Executive Officer of Rockwell Medical. “We look
forward to working with Nipro to optimize sales of Triferic in
numerous countries in Latin America and the Caribbean.”
“We welcome the opportunity to extend our
relationship with Rockwell Medical and to distribute their
important renal products to dialysis clinics in Latin America and
the Caribbean,” said Manny Zapata, Renal Division Manager Latin
America, Nipro Medical Corporation. “The region provides a
significant market opportunity, and we expect to see continued
growth in the number of patients undergoing hemodialysis in the
coming years. We look forward to working with Rockwell Medical to
grow our business in this region.”
About Rockwell Medical’s Hemodialysis
Concentrates Business
Rockwell Medical is the second largest supplier
of hemodialysis concentrates in the United States, with core
capabilities in the manufacture of hemodialysis concentrates under
cGMP conditions in three U.S. facilities, as well as in the
logistics of delivering these products to dialysis clinics
throughout most of the United States. The Company’s reputation is
based on more than 25 years of service to U.S. kidney dialysis
centers. This business segment generates about $60 million in
annual revenue. Rockwell Medical also supplies dialysis
concentrates to distributors serving a number of foreign countries,
primarily in the Americas and the Pacific Rim.
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical company
developing and commercializing its next-generation parenteral iron
technology platform, Ferric Pyrophosphate Citrate (FPC), which has
the potential to lead to transformative treatments for iron
deficiency in multiple disease states, reduce healthcare costs and
improve patients’ lives. The Company has two FDA-approved therapies
indicated for patients undergoing hemodialysis, which are the first
two products developed from the FPC platform. Rockwell Medical is
also advancing its FPC platform by developing FPC for the treatment
of iron deficiency anemia in patients outside of dialysis, who are
receiving intravenous medications in the home infusion setting. In
addition, Rockwell Medical is one of two major suppliers of
life-saving hemodialysis concentrate products to kidney dialysis
clinics in the United States. For more information, visit
www.RockwellMed.com.
Rockwell Medical Forward-Looking Statements
Certain statements in this press release may
constitute “forward-looking statements” within the meaning of the
federal securities laws, including, but not limited to, the sales
of Rockwell Concentrates in foreign jurisdictions, the ability of
NMC to market and distribute Rockwell’s products, and the ability
to reach certain minimums set forth within the contract. Words such
as, “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “could,” “can,” “would,”
“develop,” “plan,” “potential,” “predict,” “forecast,” “project,”
“intend” or the negative of these terms, and similar expressions,
or statements regarding intent, belief, or current expectations,
are forward looking statements. While Rockwell Medical believes
these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements, which
are based on information available to us on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties (including, without limitation, those set forth in
Rockwell Medical’s SEC filings), many of which are beyond our
control and subject to change. Actual results could be materially
different. Risks and uncertainties include, but are not limited to:
the impact of the COVID-19 pandemic (including, applicable
international or domestic orders), the ability to operate
Rockwell’s manufacturing facilities in a manner that avoids any
disruptions, on the ability to of RMC to secure necessary
government tenders in applicable jurisdictions; and those risks
more fully discussed in the “Risk Factors” section of our Quarterly
Report on Form 10-Q for the period ended March 31, 2021 and of our
Annual Report on Form 10-K for the year ended December 31, 2020, as
such description may be amended or updated in any future reports we
file with the SEC. Rockwell Medical expressly disclaims any
obligation to update our forward-looking statements, except as may
be required by law.
CONTACTS
Investors:Argot
Partners212.600.1902Rockwell@argotpartners.com
Media:David RosenArgot
Partners212.600.1902david.rosen@argotpartners.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024